Literature DB >> 10423342

Persistent effects of doxorubicin on cardiac gene expression.

R J Boucek1, A Miracle, M Anderson, R Engelman, J Atkinson, D A Dodd.   

Abstract

During administration of the anthracycline antitumour agents, their cardiotoxicity can progress from cardiac dysfunction to heart failure. Cardiomyopathy can also develop years after receiving anthracyclines. To determine if persistent and/or progressive anthracycline effect(s) are referable to anthracycline effects on cardiac gene expression, steady-state mRNA levels were determined 4 days (n=8), 4 weeks (n=7) and 10 weeks (n=7) after doxorubicin (DOX; 2 mg/kg IV) in a well-characterized rabbit model. Levels of mRNA for alpha -actin, beta -myosin heavy chain and the calcium pump of the sarcoplasmic reticulum (SERCA2a) in the left ventricle (LV) were determined by Northern blot hybridization and expressed relative to an 18S constitutive marker. The mRNA levels for the high molecular weight subunit (cardiac isoform) of the ryanodine receptor (RyR2), sarcolemmal calcium channel (dihydropyridine receptor; DHPR), angiotensin-converting enzyme (ACE), angiotensin II receptor (ATR) and atrial naturetic peptide prohormone (ANP) were determined by reverse transcription-polymerase chain reaction (RT-PCR) and Southern blot analysis, and expressed relative to GAPDH, a constitutive marker. Histopathologic evidence for anthracycline-induced myocardial cell injury was absent (score <1) in all hearts examined except one (score=1.1; 4 weeks post-DOX), which was considered separately. Relative mRNA levels for beta -myosin heavy chain 4 days after DOX increased 1.9-fold compared to the vehicle-treated group, but by 4 weeks levels had returned to baseline. Relative mRNA levels for DHPR were increased 1.2-fold 4 days after DOX and were persistently increased 1.9- and 2.2-fold 4 and 10 weeks after DOX, respectively. The mRNA levels for ANP were first decreased (4.5-fold) 4 days after DOX. Four weeks after DOX, ANP message levels approached Control in seven out of eight rabbits. The one rabbit with early LV histopathology 4 weeks post-DOX had increased mRNA for DHPR (2.7-fold) and ANP (80-fold). Between 4 and 10 weeks after DOX, mRNA levels for ANP increased C 16-fold: evidence for late progression. In situ hybridization with specific riboprobes localized the persistent increase in DHPR and the progressive increase in ANP to myocytes. Thus, DOX alters steady-state mRNA levels in LV that are referable to both persistent and progressive anthracycline effects on myocellular gene expression. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10423342     DOI: 10.1006/jmcc.1999.0972

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  15 in total

1.  Effect of oxidative stress on ventricular arrhythmia in rabbits with adriamycin-induced cardiomyopathy.

Authors:  Li He; Jianmin Xiao; Hui Fu; Guangsheng Du; Xing Xiao; Cuntai Zhang; Ye Gu; Yexin Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-06-09

2.  Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure.

Authors:  Orsolya Szenczi; Péter Kemecsei; Max F J Holthuijsen; Natal A W van Riel; Ger J van der Vusse; Pál Pacher; Csaba Szabó; Márk Kollai; László Ligeti; Tamás Ivanics
Journal:  Biochem Pharmacol       Date:  2005-01-12       Impact factor: 5.858

3.  Acute adriamycin-induced cardiotoxicity is exacerbated by angiotension II.

Authors:  Eylem Taskin; Elvan Kunduz Kindap; Kalender Ozdogan; Mukerrem Betul Yerer Aycan; Nurcan Dursun
Journal:  Cytotechnology       Date:  2014-07-15       Impact factor: 2.058

4.  Unbalanced upregulation of ryanodine receptor 2 plays a particular role in early development of daunorubicin cardiomyopathy.

Authors:  Dana Kucerova; Gabriel Doka; Peter Kruzliak; Katarina Turcekova; Jana Kmecova; Zuzana Brnoliakova; Jan Kyselovic; Uwe Kirchhefer; Frank U Müller; Peter Krenek; Peter Boknik; Jan Klimas
Journal:  Am J Transl Res       Date:  2015-07-15       Impact factor: 4.060

5.  Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.

Authors:  Shuang Liang; Richard C Brundage; Pamala A Jacobson; Anne Blaes; Mark N Kirstein
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

6.  Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A.

Authors:  Amy D Hanna; Alex Lam; Steffi Tham; Angela F Dulhunty; Nicole A Beard
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

Review 7.  Anthracycline-induced phospholipase A2 inhibition.

Authors:  Luther Swift; Jane McHowat; Narine Sarvazyan
Journal:  Cardiovasc Toxicol       Date:  2007       Impact factor: 3.231

Review 8.  Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Authors:  Martin Stěrba; Olga Popelová; Anna Vávrová; Eduard Jirkovský; Petra Kovaříková; Vladimír Geršl; Tomáš Simůnek
Journal:  Antioxid Redox Signal       Date:  2012-10-12       Impact factor: 8.401

9.  Melatonin Prevents Mitochondrial Damage Induced by Doxorubicin in Mouse Fibroblasts Through Ampk-Ppar Gamma-Dependent Mechanisms.

Authors:  Celal Guven; Eylem Taskin; Handan Akcakaya
Journal:  Med Sci Monit       Date:  2016-02-10

10.  Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up.

Authors:  Olga Lenčová-Popelová; Eduard Jirkovský; Yvona Mazurová; Juraj Lenčo; Michaela Adamcová; Tomáš Šimůnek; Vladimír Geršl; Martin Štěrba
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.